Grassley probes journals for ghostwriting info

Share this article:
Sen. Chuck Grassley (R-IA) asked eight journals to provide information about their medical ghostwriting practices and policies, in an effort to “shed light on the role companies may play in the dissemination of information about their products through medical literature.”

Grassley's most recent probe into ghost writing practices took the form of a letter sent to the American Journal of Medicine, the Annals of Internal Medicine, the Annual Review of Medicine, the New England Journal of Medicine, JAMA and others.

The letter, dated July 2, requested that publishers detail their editorial policies with respect to third parties involved in the “development and/or writing of a journal article,” and any actions taken against an author for failing to disclose this information. Grassley asked that all of the journals respond by July 22.

“Public dollars and the public trust are at stake in the practice of medicine, and the information that is shared in these journals can influence decisions made by doctors and their patients,” said Grassley in a release. “Transparency can do a lot of good in building confidence that there's nothing to hide, and that applies to how expert opinion is presented in public forums like these journals provide.”

In the past, Grassley has requested ghostwriting-related information from Wyeth and Merck over allegations that both companies signed authors on to published articles and clinical research inappropriately.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...